Karleen Marie Oberton Sells 4,704 Shares of Hologic, Inc. (HOLX) Stock

Hologic, Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Hologic, Inc. (NASDAQ:HOLX) opened at 45.41 on Friday. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The company’s 50-day moving average is $45.08 and its 200 day moving average is $42.70. The firm has a market cap of $12.72 billion, a PE ratio of 16.28 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The business had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same period in the previous year, the firm posted $0.47 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. Equities analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at [[permalink]].

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank increased its stake in shares of Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock worth $43,747,000 after buying an additional 195,100 shares during the period. Earnest Partners LLC increased its stake in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock valued at $8,734,000 after buying an additional 205,138 shares during the last quarter. Lincoln Capital Corp purchased a new stake in Hologic during the fourth quarter valued at $377,000. KAMES CAPITAL plc purchased a new stake in Hologic during the first quarter valued at $718,000. Finally, LS Investment Advisors LLC increased its stake in Hologic by 10.9% in the first quarter. LS Investment Advisors LLC now owns 12,890 shares of the medical equipment provider’s stock valued at $548,000 after buying an additional 1,268 shares during the last quarter. 94.04% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on HOLX. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up from $50.00) on shares of Hologic in a research report on Monday. Piper Jaffray Companies reissued a “buy” rating and set a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. Finally, Leerink Swann reissued an “outperform” rating and set a $52.00 target price on shares of Hologic in a research note on Thursday, March 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. Hologic has an average rating of “Buy” and a consensus price target of $47.77.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.